home / stock / arqt / arqt quote
Last: | $8.75 |
---|---|
Change Percent: | -0.92% |
Open: | $8.82 |
Close: | $8.75 |
High: | $9.1 |
Low: | $8.74 |
Volume: | 1,792,516 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$8.75 | $8.82 | $8.75 | $9.1 | $8.74 | 1,792,516 | 04-24-2024 |
$8.74 | $9.02 | $8.74 | $9.295 | $8.72 | 1,591,897 | 04-23-2024 |
$8.94 | $9.18 | $8.94 | $9.28 | $8.7425 | 1,227,500 | 04-22-2024 |
$9.1 | $9.36 | $9.1 | $9.455 | $8.435 | 4,520,740 | 04-19-2024 |
$9.45 | $10.3 | $9.45 | $10.38 | $9.31 | 2,918,549 | 04-18-2024 |
$10.25 | $10.18 | $10.25 | $10.34 | $9.97 | 2,515,933 | 04-17-2024 |
$10.1 | $9.91 | $10.1 | $10.33 | $9.75 | 1,859,563 | 04-16-2024 |
$10.09 | $10.18 | $10.09 | $10.465 | $9.95 | 2,688,210 | 04-15-2024 |
$10.2 | $11.77 | $10.2 | $11.7787 | $9.82 | 4,161,247 | 04-12-2024 |
$11.88 | $12.38 | $11.88 | $12.56 | $11.81 | 2,736,712 | 04-11-2024 |
$12.34 | $11.7828 | $12.34 | $12.47 | $11.41 | 2,792,661 | 04-10-2024 |
$12.49 | $12.48 | $12.49 | $13.17 | $12.3 | 3,992,637 | 04-09-2024 |
$12.53 | $11.39 | $12.53 | $12.62 | $11.3 | 4,911,776 | 04-08-2024 |
$11.34 | $10.66 | $11.34 | $11.79 | $10.38 | 3,471,193 | 04-05-2024 |
$10.75 | $9.74 | $10.75 | $10.865 | $9.7348 | 4,069,591 | 04-04-2024 |
$9.63 | $9.37 | $9.63 | $9.78 | $9.2 | 1,642,479 | 04-03-2024 |
$9.4 | $9.4 | $9.4 | $9.48 | $9.28 | 2,019,329 | 04-02-2024 |
$9.68 | $9.96 | $9.68 | $10 | $9.16 | 3,075,274 | 04-01-2024 |
$9.91 | $9.67 | $9.91 | $10.02 | $9.61 | 3,723,645 | 03-29-2024 |
$9.91 | $9.67 | $9.91 | $10.02 | $9.61 | 3,723,645 | 03-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
Arcutis Biotherapeutics Inc. Company Name:
ARQT Stock Symbol:
NASDAQ Market:
WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage company focused on...
WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper has been appointed Chief Financial Officer (CFO) effe...
NESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved lar...